Omar Castaneda Puglianini, MD, discusses results from the phase 1b/2 CARTITUDE-1 trial evaluating ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma.
Omar Castaneda Puglianini, MD, hematology and medical oncologist at Moffitt Cancer Center, discusses results from the phase 1b/2 CARTITUDE-1 trial (NCT03548207) evaluating ciltacabtagene autoleucel (cilta-cel) in patients with relapsed/refractory multiple myeloma.
Results from the study showed that the overall response rate (ORR) was 97.9%, Castaneda Puglianini says. With longer follow-up, responses to the CAR T-cell therapy deepened. The stringent complete response (sCR) rate increased from 67% at a median follow-up of 8 to 9 months, to 80.4% at 18 months, Castaneda Puglianini notes.
The median duration of response with the agent was 21.8 months, and the median progression-free survival (PFS) was 22.8 months, Castaneda Puglianini adds. Notably, for patients who achieved a sCR, the median PFS was not reached. Response rates were also comparable across patient subgroups, including those who received previous lines of therapy and extramedullary disease. Overall, the efficacy demonstrated by cilta-cel on this study was impressive, Castaneda Puglianini concludes.